Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | TACR3 | P29371 | 12/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | TACR2 | P21452 | 8/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6625208 | 0.84 | LMNA (0.53) | LMNATP53TACR3TACR2OPRM1 | |
| SCHEMBL6629501 | 0.84 | TACR3 (0.43) | LMNATP53TACR3TACR2OPRM1 | |
| SCHEMBL6626579 | 0.83 | ALDH1A1 (0.56) | LMNATP53TACR3TACR2OPRM1 | |
| SCHEMBL7003424 | 0.81 | LMNA (0.50) | LMNATP53TACR3TACR2OPRM1 | |
| SCHEMBL5440405 | 0.80 | PDE10A (0.54) | LMNATP53TACR3TACR2 | |
| SCHEMBL4667076 | 0.79 | LMNA (0.48) | LMNATP53TACR3TACR2OPRM1 | |
| SCHEMBL4665926 | 0.79 | LMNA (0.48) | LMNATP53TACR3TACR2OPRM1 | |
| SCHEMBL5042680 | 0.79 | LMNA (0.47) | LMNATP53TACR3TACR2OPRM1 | |
| SCHEMBL7096193 | 0.78 | TACR3 (0.69) | TACR3TACR2OPRM1 | |
| SCHEMBL7164730 | 0.77 | TACR3 (0.60) | TACR3TACR2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377567-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GlaxoSmithKline S.p.A. (IT) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002083663-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. (IT) | 2002-10-24 | — | — | WO | disclosed |